Filing Details
- Accession Number:
- 0000891293-11-000004
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-02-02 19:21:08
- Reporting Period:
- 2011-01-31
- Filing Date:
- 2011-02-02
- Accepted Time:
- 2011-02-02 19:21:08
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
891293 | Cell Therapeutics Inc | CTIC | Pharmaceutical Preparations (2834) | 911533912 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1041084 | Phd M Phillip Nudelman | 501 Elliott Ave W, #400 Seattle WA 98119 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2011-01-31 | 2,553 | $0.35 | 2,312,312 | No | 4 | S | Direct | |
Common Stock | Disposition | 2011-01-31 | 10,200 | $0.35 | 2,302,112 | No | 4 | S | Direct | |
Common Stock | Disposition | 2011-01-31 | 12,727 | $0.35 | 2,289,385 | No | 4 | S | Direct | |
Common Stock | Disposition | 2011-01-31 | 6,600 | $0.35 | 2,282,785 | No | 4 | S | Direct | |
Common Stock | Disposition | 2011-01-31 | 4,500 | $0.35 | 2,278,285 | No | 4 | S | Direct | |
Common Stock | Disposition | 2011-01-31 | 300 | $0.36 | 2,277,985 | No | 4 | S | Direct | |
Common Stock | Disposition | 2011-01-31 | 2,420 | $0.36 | 2,275,565 | No | 4 | S | Direct | |
Common Stock | Disposition | 2011-01-31 | 500 | $0.36 | 2,275,065 | No | 4 | S | Direct | |
Common Stock | Disposition | 2011-01-31 | 200 | $0.36 | 2,274,865 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.